Vor Biopharma Inc. (VOR)

Vor Biopharma is a pre-revenue, clinical-stage biotech now focused on telitacicept, with progress driven by clinical and regulatory milestones. SEC filings show strong liquidity (about $492M in cash and marketable securities at 3/31/2026) and management guidance that cash can fund plans into early 2029, but the company remains highly loss-making and subject to large non-cash swings from warrant-liability remeasurement. With outcomes dependent on Phase 3 results/approvals and meaningful dilution/volatility risk, this screens as speculative despite the cash runway (fundamentalScore: 2/5). Standardized valuation ratios and DCF outputs were not available in this run, so the score leans heavily on SEC-reported liquidity and risk disclosures.

Short-term sentiment is muted: the only clear near-term catalyst surfaced is VOR’s reported Russell Microcap Index inclusion (technical, announced), while company-driven news flow is otherwise quiet. Media tone over the last ~14d is neutral/slightly positive but a bit less constructive than the modestly positive 30–90d baseline; legal screen is clean and retail sentiment is indeterminate due to Reddit rate-limits.

Trend and participation are strong: VOR trades above SMA20/50/200, EMA9/21, and daily VWAP, with MACD positive above signal and ADX confirming trend strength. The weak spot is extension—RSI14 at 70.16 and Williams %R at -13.17 show the stock is near-term overbought after a sharp range expansion.